LPTX241220C6000
- 0.40
- 0.000.00%
Leap Therapeutics Newsroom
Leap Therapeutics Analyst Ratings
H.C. Wainwright Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $5.5
Baird Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $9
Optimistic Buy Rating on Leap Therapeutics Amid Promising Phase 2 Cancer Trial Outcomes
Leap Therapeutics Analyst Ratings
H.C. Wainwright Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $5.5
Leap Therapeutics: Runway To Fund Operating, Capital Spending Into 2Q 2026 >LPTX
Leap Therapeutics Analyst Ratings
Buy Rating Affirmed for Leap Therapeutics on Strong Trial Prospects and Solid Financials
Leap Therapeutics Analyst Ratings
Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating
Leap Therapeutics Analyst Ratings
Leap Therapeutics: Promising Clinical Outcomes and Upcoming Catalysts Bolster Buy Rating
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), Leap Therapeutics (LPTX)
Outperform Rating on Leap Therapeutics Amid Promising Gastric Cancer Trial Outcomes
Analysts Offer Insights on Healthcare Companies: Sensus Healthcare (SRTS), Outlook Therapeutics (OTLK) and Leap Therapeutics (LPTX)
Analysts Offer Insights on Healthcare Companies: Codexis (CDXS), Leap Therapeutics (LPTX) and Sutro Biopharma (STRO)
Leap Therapeutics (LPTX) Gets a Buy From Piper Sandler
Optimism High as Leap Therapeutics' Studies Suggest Potential for Significant Shareholder Value
Leap Therapeutics (LPTX) Receives a Buy From Piper Sandler